A Randomized Phase 3 Study Comparing <scp>P2B001</scp> to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's Disease
C. Warren Olanow(Icahn School of Medicine at Mount Sinai), Lawrence Elmer(University of Toledo), David Kreitzman(Centre for Movement Disorders), Andrew McGarry(Cooper Medical School of Rowan University), Ramon Gil(Centre for Movement Disorders), Karl Kieburtz(University of Rochester), Daniel J. Burdick, Robert A. Hauser(University of South Florida), Rohit Dhall(University of Arkansas for Medical Sciences), Joy Antonelle de Marcaida(Centre for Movement Disorders)
Cited by 5
Related Papers
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
|New England Journal of Medicine|2009|889
Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss
|JAMA|2014|538
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
|The Lancet Neurology|2015|508
The Idiopathic Intracranial Hypertension Treatment Trial
|JAMA Neurology|2014|475